Stock AnalizAlnylam Pharmaceuticals, Inc. ALNY
Biotechnology: Pharmaceutical Preparations · IPO 2004 · data as of November 13, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) is a healthcare company listed in the US with a market value of about $22.1B. In the twelve months to September 30, 2026 it had revenue of $5.0B and net income of $2.6B, a net margin of 52.8%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 8.6, a price to free cash flow of 27.4, 5-year revenue growth of 50% a year, a 5-year average ROIC of -24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 34% above the current price.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- P/FCF below 20
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Interest covered more than 5 times
- Liabilities below 60% of assets
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0B | $3.7B | $2.2B | $1.8B | $1.0B | $844M | $493M | $220M | $75M | $90M | $47M |
| Net income | $2.6B | $314M | -$278M | -$440M | -$1.1B | -$853M | -$858M | -$886M | -$761M | -$491M | -$410M |
| Free cash flow | $806M | $465M | -$43M | $42M | -$613M | -$718M | -$685M | -$419M | -$690M | -$487M | -$372M |
| EPS (diluted) | $19.24 | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | $-7.57 | $-5.42 | $-4.79 |
| Net margin | 52.8% | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | -546.0% | -869.6% |
| ROIC | — | 23.5% | -9.6% | -20.5% | -53.4% | -61.5% | -42.6% | -42.6% | -48.3% | -27.8% | -39.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 27 analysts is $299.96, 82% above the current price; targets range from $180.00 to $455.00; the consensus rating is “Buy”; expected EPS is $22.68 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Alnylam Pharmaceuticals’s P/E ratio?
About 8.6, based on the last twelve months of diluted earnings per share (forward P/E about 15.8).
Is Alnylam Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 34% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Alnylam Pharmaceuticals pay a dividend?
Not currently.
Is Alnylam Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Alnylam Pharmaceuticals scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.